Cited 0 times in
유방암 환자에서 종양 표지자로서 혈액내 TGF-β1의 분포에 관한 연구
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 라선영 | - |
dc.contributor.author | 정현철 | - |
dc.date.accessioned | 2020-07-02T17:33:16Z | - |
dc.date.available | 2020-07-02T17:33:16Z | - |
dc.date.issued | 1998 | - |
dc.identifier.issn | 0496-6872 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/176888 | - |
dc.description.abstract | PURPOSE: Transforming Growth Factor-beta1(TGF-beta1) is the most potent inhibitor of the progression of normal mammary epithelial cells through the cell cycle. However, advanced breast cancers are mostly refractory to TGF-beta mediated growth inhibition and produce large amounts of TGF-beta, which may enhance tumor cell invasion and metastasis by its effects on extracellular matrix. Yet, little is known about the association of TGF-beta1 with progression of malignant disease in vivo. In this study, we evaluated the preoperative and postoperative plama level of TGF- in breast cancer and analyzed the utility of plasma TGF-beta1 as possible tumor marker. MATERIALS AND METHODS: ELISA(enzyme-linked immunosorbent assay) was used to measure plasma TGF-beta1 level in 45 newly diagnosed breast cancer patients and in 15 normal healthy people, and the results were compared with clinicopathologic characteristics. RESULTS: The mean plasma TGF-beta1 levels were 1.73+/-0.47 ng/ml in normal people and 5.05+/-1.41 ng/ml in breast cancer patiens. In 37 operated patients, the preoperative plasma TGF-beta1 level was 6.34+/-1.34 ng/ml and decreased to 4.48+/-1.07 ng/ml in patients with follow-up after surgery and 4.74+/-0.79 ng/ml in patients with chemotherapy. However, there was no significant correlation between plasma TGF-beta1 level and known prognostic factors including tumor size, LN involvement, tumor grade, hormone receptor status, and pathology. CONCLUSION: These findings suggest that the plasma TGF-g level can be a tumor marker in breast cancer patients and the association with progression of breast cancer will be explored in future studies. | - |
dc.description.statementOfResponsibility | open | - |
dc.language | Korean | - |
dc.publisher | 대한암학회 | - |
dc.relation.isPartOf | Journal of the Korean Cancer Association (대한암학회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 유방암 환자에서 종양 표지자로서 혈액내 TGF-β1의 분포에 관한 연구 | - |
dc.title.alternative | Plasma TGF-beta1 as a Tumor Marker in Breast Cancer Patients | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | 이화영 | - |
dc.contributor.googleauthor | 라선영 | - |
dc.contributor.googleauthor | 공수정 | - |
dc.contributor.googleauthor | 안중배 | - |
dc.contributor.googleauthor | 심광용 | - |
dc.contributor.googleauthor | 박준오 | - |
dc.contributor.googleauthor | 권현자 | - |
dc.contributor.googleauthor | 유내춘 | - |
dc.contributor.googleauthor | 정숙정 | - |
dc.contributor.googleauthor | 정현철 | - |
dc.contributor.googleauthor | 김주항 | - |
dc.contributor.googleauthor | 이경식 | - |
dc.contributor.googleauthor | 민진식 | - |
dc.contributor.googleauthor | 김병수 | - |
dc.contributor.googleauthor | 노재경 | - |
dc.contributor.localId | A01316 | - |
dc.contributor.localId | A03773 | - |
dc.relation.journalcode | J01813 | - |
dc.subject.keyword | TGF-beta | - |
dc.subject.keyword | Breast cancer | - |
dc.subject.keyword | Carcinogenesis | - |
dc.subject.keyword | Tumor marker | - |
dc.subject.keyword | Prognostic factor | - |
dc.contributor.alternativeName | Rha, Sun Young | - |
dc.contributor.affiliatedAuthor | 라선영 | - |
dc.contributor.affiliatedAuthor | 정현철 | - |
dc.citation.volume | 30 | - |
dc.citation.number | 5 | - |
dc.citation.startPage | 935 | - |
dc.citation.endPage | 942 | - |
dc.identifier.bibliographicCitation | Journal of the Korean Cancer Association (대한암학회지), Vol.30(5) : 935-942, 1998 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.